. Roberto Ezequiel Heymann and Eduardo dos Santos Paiva received honorariums from Lilly, Janssen-Cilag, Boehringer, Apsen, and Pfizer for speeches and consulting services; Milton Helfenstein Junior received honorariums from Pfizer and Merck Sharp for speeches and consulting services; Daniel Feldman Pollak received honorariums from Lilly, Pfizer, and Merck Sharp; José Eduardo Martinez received honorariums from Sanofi Aventis, for speeches, and Pfizzer, for speeches and consulting services; José Roberto Provenza received honorariums from Roche, Bristol, Ache, and Pfizer to participate in clinical studies with new drugs at PUC-Campinas; Marcelo Cruz Rezende received honorariums from LillyBoehringer, to participate in symposiums, and from Pfizer, for speeches and to participate in sympostiums; valério valim Cristo received honorariums from Roche for presentations, conferences, or speeches, besides financing for studies, teaching organization, or to attend symposiums sponsored by Lilly, Genzyme, and Schering-Plough.

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

Background: Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years. Due to its potent inhibition of the dominant apical (luminal) urate exchanger in the human proximal tubule URAT1, it reduces the urate reabsorption, diminishing serum urate levels and therefore preventing gout flares. Main body of the abstract: Through several clinical trials, Benzbromarone has been proved effective and safe, inclusive in patients with chronic kidney disease and as combination therapy with allopurinol. Due to hepatotoxicity reports, it was withdrawn from the European market by the manufacturer, however many authors have questioned the product's withdrawal due to a lack of clinical evidence in order to support its hepatotoxicity. Benzbromarone is still available in several European countries, New Zealand, Brazil and several other countries. Despite the product's marketing over more than 20 years after the first hepatotoxicity reports, we have found only five reports in our literature search, and no prospective or retrospective study correlating hepatotoxicity with benzbromarone use. Short conclusion: Benzbromarone is a safe and effective molecule for the treatment of gout. However, due to in vitro and in vivo data related to hepatotoxicity, it is prudent to prescribe it with some caution, especially for patients with an already known liver condition.

Women with FM showed a lower qualitative and quantitative intake in comparison with CT group. Only vitamin E correlated with quality of life and percentage of protein in the diet with sensation of pain.

Introduction: Depression is one of the most frequent psychiatric comorbidities in patients with fi bromyalgia (FM), and chronic stress might be one of the triggering events of the characteristic FM symptoms. Objectives: To compare depressive symptoms and stress perception between women with and without FM, in addition to investigate the relationship between those characteristics and the functionality and the impact on the quality of life of those patients. Methods: The study included 20 women with FM (FM group) and 20 healthy women (control group). The following instruments were used: Beck Depression Inventory, Perceived Stress Scale-10, Health Assessment Questionnaire, Fibromyalgia Impact Questionnaire, and Visual Analogue Scale for pain (0-10 cm). Results: The FM group showed higher severity of the depressive symptoms (24.10 ± 11.68) and greater perception of stress (25.10 ± 4.82) as compared with those of the control group (10.20 ± 12.78, P < 0.01; and 15.45 ± 7.29, P < 0.01; respectively). A higher incidence of depressive symptoms was observed in the FM group (75%) than in the control group (25%) (χ 2 = 10.00, P < 0.01). In the FM group, a positive correlation was observed between the depressive symptoms and perceived stress (r = 0.54, P < 0.05), pain (r = 0.58, P < 0.01), impaired functionality (r = 0.56, P < 0.01), and impact on the quality of life (r = 0.46, P < 0.05). In this group there was also correlation between perceived stress and impaired functionality (r = 0.50; P < 0.05). Pain showed no relationship with perceived stress. Conclusion: The relationship between stress, depression and functionality seems to be part of a complex mechanism, which might affect the quality of life of patients with FM.